SelectScience
Join Free
Accelerating Science
NewsLife Sciences

PhoreMost and Oxford Biomedica enter gene therapy discovery collaboration

PhoreMost

Collaboration to develop next-generation CAR-T cell therapies with improved efficacy and durability

12 Nov 2020
Tom Casburn
Associate Editor

Industry news

Dr. Chris Torrance, CEO, PhoreMost, & John Dawson, CEO, Oxford Biomedica

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Oxford Biomedica, a leading gene and cell therapy group, have announced that they have entered into a discovery collaboration to develop next-generation CAR-T cell therapies. Financial details of the agreement are not disclosed.

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER®, to identify therapeutic candidates for Oxford Biomedica’s LentiVector® gene therapy delivery system. The program will initially focus on CAR-T therapy and aims to develop next-generation cell therapies with significantly improved efficacy and durability.

Dr. Chris Torrance, CEO, PhoreMost, said: “This collaboration with Oxford Biomedica, a global pioneer in cell and gene therapies, is further recognition of the power of SITESEEKER®, offering an exciting opportunity to discover and accelerate the development of clinical-stage products. The natural complementarity between SITESEEKER® and LentiVector® offers great promise for this and future collaborations between the two companies.”

John Dawson, CEO of Oxford Biomedica, said: “We are excited to apply this next-generation technology to our LentiVector® platform. The collaboration has the potential to deliver more effective CAR-T therapies, and we look forward to working closely with the PhoreMost team.”

SITESEEKER® exploits protein shape diversity to find functionally active peptides linked to any chosen disease setting, significantly enhancing the power of phenotypic screening and translation into therapeutic modalities. Based on proprietary protein interference, or ‘PROTEINi®’, technology, SITESEEKER® is able to systematically probe the entire proteome in a live cell environment to identify and exploit novel drug targets.

Oxford Biomedica is a world-leading pioneer of cell and gene therapies. Its LentiVector® platform enables the successful development of breakthrough gene and cell-based medicines, and through collaborations with pharmaceutical partners, has delivered the first FDA and EMA approved CAR-T cell therapy.

Want more of the latest science news straight to your inbox? Become a SelectScience member today for free>>

Links

PhoreMostCompany website

Tags

Cell Lines Stem Cells and Primary CellsPrimary cell cultures, established cell lines and stem cells are vital for <i>in vitro</i> and <i>ex vivo</i> experimentation. High-quality cells, optimized for your applications, alongside optimized cell substrates, growth medium and supplements, are critical for experimental success. Explore a range of cells suitable for your applications, including isogenic cell lines, competent cells, induced pluripotent stem cell (iPSC)-derived cell lines, fungal/bacterial/mammalian cell lines, stem cells and cancer cell lines. Find the best cells for your research in our peer-reviewed product directory: compare products, check customer reviews and receive pricing direct from manufacturers.Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.Clinical TrialsClinical Trials, an essential part of drug discovery process, assess the safety and effectiveness of a new medication or device in the pharmaceutical industry. Clinical Trials are a phased process (Phase 0, Phase I, Phase II, Phase III and Phase IV) which begins after initial preclinical testing.Cell TherapyCell therapy involves using living cells to treat diseases, often by replacing damaged cells or stimulating regeneration. Stem cell therapy and CAR-T cell therapy are examples of cutting-edge treatments in regenerative medicine and cancer immunotherapy. Browse our peer-reviewed product directory to find the best cell therapy tools, compare products, check reviews, and get pricing directly from manufacturers.TherapeuticsTherapeutics are treatments designed to alleviate or cure diseases. These include pharmaceuticals, biologics, and gene therapies, which work by targeting specific disease mechanisms. Advances in personalized medicine and biologics offer new hope for patients with conditions that were previously difficult to treat. Browse our peer-reviewed product directory to find therapeutic solutions for various diseases; compare products, check user reviews, and get pricing directly from manufacturers.Gene TherapyGene therapy is a technique that modifies or replaces genes within an individual's cells to treat or prevent diseases. This approach holds potential for curing genetic disorders, cancers, and certain viral infections. Advances in gene editing technologies like CRISPR are driving the growth of gene therapy. Explore gene therapy tools and technologies in our peer-reviewed product directory; compare products, check reviews, and get pricing directly from manufacturers.T Cells

Related articles

PhoreMost and Oxford Biomedica enter gene therapy discovery collaboration